

REMARKS

At the outset, applicants would like to thank Examiner Habte and Primary Examiner Berch for their time and consideration of the present application at the interview with the undersigned attorney.

Claims 1-8, 10-11, 13-14 and 17 are pending in the present application. Claims 1 and 3 have been amended to more particularly point out and distinctly claim the present invention. Claim 14 has been amended to incorporate the subject matter of claim 12. Claim 16 has been amended to incorporate the subject matter of claim 15. Claims 12, 15 and 16 have been canceled.

In the outstanding Official Action, claims 12 and 15-16 were rejected under 35 USC 112, first paragraph for allegedly failing to comply with the written description requirement. Applicants believe that the present amendment obviates this rejection.

In imposing the rejection, the Official Action alleged that the phrase "an hematological malignancy" lacked descriptive support. However, as noted above, claims 12, 15, and 16 have been canceled.

While claim 17 has been added, claim 17 incorporates the subject matter of previous claims 15 and 16 with the exception that claim 17 has been drafted in a manner so that the

claim does not recite the phrase "an hematological malignancy". Thus, in view of the above, applicants believe that the present amendment obviates this rejection. Moreover, applicants believe that claim 17 is supported by the present disclosure.

Claim 12 is rejected under 35 USC 112, first paragraph, as allegedly failing to comply with the enablement requirement. However, as noted above, claim 12 has been canceled.

Claims 1-8 and 10-16 were rejected under 35 USC 112, second paragraph as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants believe that the present amendment obviates this rejection.

The Official Action alleged that claims 1 and 3 were indefinite for reciting the phrase "groups of type (C₁-C₆) alkyl". However, claims 1 and 3 have been amended so that this phrase is no longer recited. As a result, applicants believe that claims 1 and 3 are definite to one of ordinary skill in the art.

The Official Action also objected to claim 14 for reciting the phrase "includes". The Official Action alleged that it was unclear whether the recitation that followed the phrase was part of the claimed invention. However, claim 14 has been amended so that this phrase is no longer recited.

Claims 14 and 16 were also objected to for reciting the term "globlastomas". The Examiner pointed out that the term


should be "glioblastomas". In accordance with the Examiner's suggestion, claims 14 and 17 have been amended and written to recite "glioblastomas". Applicants would like to thank the Examiner for a suggestion as to how to overcome this objection.

Thus, in view of the above, applicants believe that the present application is in condition for allowance, with claims 1-8, 10-11, 13-14 and 17. Allowance and passage to issue on that basis are accordingly respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Philip Dubois, Reg. No. 50,696
Attorney for Applicants
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

PD/fb